Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences

Gene Therapy

Volumn 10, Issue 11 SPEC., 2003, Pages 946-954

  Lowenstein, P R ^a,b   Castro, M G ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 1; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; CYTOKINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; BRAIN TISSUE; CELL INFILTRATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENCEPHALITIS; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BRAIN; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ADENOVIRIDAE;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIGENS, VIRAL; BRAIN; CYTOKINES; ENCEPHALITIS; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENTRICULAR; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS;

EID: 0038128348     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302048     Document Type: Review

References (73)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
2. Lowenstein PR, Castro MG. Progress and challenges in viral vector-mediated gene transfer to the brain. Curr Opin Mol Ther 2002; 4: 359-371.
3. Medzhitov R, Janeway Jr CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
4. Yewdell JW, Norbury CC, Bennink JR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999; 73: 1-77.
5. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003; 3: 36-50.
6. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000; 21: 447-455.
7. Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat Immunol 2002; 3: 1019-1025.
8. Tortorella D et al. Viral subversion of the immune system. Annu Rev Immunol 2000; 18: 861-926.
9. Oldstone MB. Travels along the viral-immunobiology highway. Immunol Rev 2002; 185: 54-68.
10. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002; 14: 523-536.
11. Zinkernagel RM. Uncertainties - discrepancies in immunology. Immunol Rev 2002; 185: 103-125.
12. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 2002; 23: 23-30.
13. Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol 1998; 90: 113-21.
14. Shirai Y. On the transplantation of the rat sarcoma in adult heterogenous animals. Jpn Med World 1921; 1: 14-15.
15. Murphy JBS, E. Conditions determining the transplantability of tissues in the brain. J Exp Med 1923; 38: 183-97.
16. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 58-69.
17. Byrnes AP, Rusby JE, Wood MJ, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015-1024.
18. Wood MJ et al. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 1996; 19: 497-501.
19. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 1996; 16: 3045-3055.
20. Cartmell T et al. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J Neurosci 1999; 19: 1517-1523.
21. Byrnes AP, Wood MJ, Charlton HM. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Therapy 1996; 3: 644-651.
22. Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
23. Raper SE et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-175.
24. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/ MAPK signaling pathway and induces interleukin-8 expression. J Virol 1997; 71: 398-404.
25. Borgland SL et al. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 2000; 74: 3941-3947.
26. Bowen GP et al. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum Gene Ther 2002; 13: 367-379.
27. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
28. Tibbles LA et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 2002; 76: 1559-1568.
29. Thomas CE et al. Acute direct adenoviral vector cytotoxicity and chronic but not acute inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 2001; 3: 36-46.
30. Thomas CE et al. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J Virol 2002; 76: 3452-60.
31. Thomas CE et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97: 7482-7478.
32. Thomas CE et al. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 2001; 12: 839-846.
33. Kajiwara K et al. Humoral immune responses to adenovirus vectors in the brain. J Neuroimmunol 2000; 103: 8-15.
34. Thomas CE et al. Gene transfer into rat brain using adenoviral vectors. In: Gerfen JN, McKay R, Rogawski MA, Sibley DR, Skolnick P. (eds) Current Protocols in Neuroscience, John Wiley and Sons: New York, NY; 2000, pp 4.23.1-4.40.
35. Roelvink PW et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
36. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-114.
37. Lassmann H. Classification of demyelinating diseases at the interface between etiology and pathogenesis. Curr Opin Neurol 2001; 14: 253-258.
38. Lucchinetti C et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
39. Coesmans M et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53: 325-336.
40. Stuerzebecher S, Martin R. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis. Neuroimaging Clin N Am 2000; 10: 649-68,vii-viii.
41. Matyszak MK, Perry VH. A comparison of leucocyte responses to heat-killed bacillus Calmette-Guerin in different CNS compartments. Neuropathol Appl Neurobiol 1996; 22: 44-53.
42. Matyszak MK, Perry VH. Bacillus Calmette-Guerin sequestered in the brain parenchyma escapes immune recognition. J Neuroimmunol 1998; 82: 73-80.
43. Stevenson PG, Austyn JM, Hawke S. Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma. J Gen Virol 2002; 83: 1735-1743.
44. Stevenson PG, Bangham CR, Hawke S. Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site. Eur J Immunol 1997; 27: 3259-3268.
45. Stevenson PG, Freeman S, Bangham CR, Hawke S. Virus dissemination through the brain parenchyma without immunologic control. J Immunol 1997; 159: 1876-1884.
46. Stevenson PG, Hawke S, Sloan DJ, Bangham CR. The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 1997; 71: 145-151.
47. Newman TA et al. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001; 124: 2203-2214.
48. Harling-Berg CJ, Park TJ, Knopf PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999; 101: 111-127.
49. Cserr HF et al. Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal bloodbrain barrier permeability. J Neuroimmunol 1992; 41: 195-202.
50. Carson MJ, Reilly CR, Sutcliffe JG, Lo D. Disproportionate recruitment of CD8+ T cells into the central nervous system by professional antigen-presenting cells. Am J Pathol 1999; 154: 481-494.
51. Fischer HG, Bielinsky AK. Antigen presentation function of brain-derived dendriform cells depends on astrocyte help. Int Immunol 1999; 11: 1265-1274.
52. Fischer HG, Bonifas U, Reichmann G. Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol 2000; 164: 4826-4834.
53. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001; 166: 2717-2726.
54. Lowe J et al. Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells. J Pathol 1989; 159: 143-149.
55. Matyszak MK, Perry VH. The Potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 1996; 74: 599-608.
56. McMenamin PG. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol 1999; 405: 553-562.
57. Santambrogio L et al. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001; 98: 6295-6300.
58. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000; 157: 1991-2002.
59. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
60. Tompkins SM, Fuller KG, Miller SD. Theiler's virus-mediated autoimmunity: local presentation of CNS antigens and epitope spreading. Ann N Y Acad Sci 2002; 958: 26-38.
61. Hart DN, Fabre JW. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med 1981; 154: 347-361.
62. McMenamin MM et al. A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 1998; 83: 1225-1237.
63. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477-486.
64. Maione D et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986-5991.
65. Molinier-Frenkel V et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678-7682.
66. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol 1996; 70: 6733-6740.
67. Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
68. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
69. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
70. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
71. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564-2570.
72. Wadsworth SC, Zhou H, Smith AE, Kaplan JM. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J Virol 1997; 71: 5189-5196.
73. Guidotti LG, Chisari FV. Non-cytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.